The New England journal of medicine
-
Editorial Comment
A Challenge to Respiratory Syncytial Virus Illness in Adults.
-
Randomized Controlled Trial
Vaccine Efficacy in Adults in a Respiratory Syncytial Virus Challenge Study.
Although human respiratory syncytial virus (RSV) is an important cause of illness and death in older adults, no RSV vaccine has been licensed. ⋯ RSVpreF vaccine was effective against symptomatic RSV infection and viral shedding. No evident safety concerns were identified. These findings provide support for further evaluation of RSVpreF vaccine in a phase 3 efficacy study. (Funded by Pfizer; EudraCT number, 2020-003887-21; ClinicalTrials.gov number, NCT04785612.).